Literature DB >> 3344943

Isoflurane and primary pulmonary hypertension.

D C Cheng1, G Edelist.   

Abstract

Primary pulmonary hypertension is a rare and fatal disease. These patients represent an anaesthetic challenge because of the high mortality associated with the marked intra-operative increase in pulmonary vascular resistance and right ventricular decompensation. This is a first case report which demonstrates the safe and beneficial effects of isoflurane in lowering pulmonary arterial pressure and pulmonary vascular resistance in such a patient for a short surgical procedure. The anaesthetic considerations in these patients are discussed.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3344943     DOI: 10.1111/j.1365-2044.1988.tb05417.x

Source DB:  PubMed          Journal:  Anaesthesia        ISSN: 0003-2409            Impact factor:   6.955


  4 in total

1.  Pulmonary exposure to peat smoke extracts in rats decreases expiratory time and increases left heart end systolic volume.

Authors:  Leslie C Thompson; Yong Ho Kim; Brandi L Martin; Allen D Ledbetter; Janice A Dye; Mehdi S Hazari; M Ian Gilmour; Aimen K Farraj
Journal:  Inhal Toxicol       Date:  2019-01-15       Impact factor: 2.724

2.  Compensated right ventricular function of the onset of pulmonary hypertension in a rat model depends on chamber remodeling and contractile augmentation.

Authors:  Daniela Vélez-Rendón; Xiaoyan Zhang; Jesse Gerringer; Daniela Valdez-Jasso
Journal:  Pulm Circ       Date:  2018-09-03       Impact factor: 3.017

3.  Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Perioperative management in patients with pulmonary hypertension.

Authors:  Adriano R Tonelli; Omar A Minai
Journal:  Ann Thorac Med       Date:  2014-07       Impact factor: 2.219

4.  Perioperative events in children with pulmonary hypertension undergoing non-cardiac procedures.

Authors:  Meghan L Bernier; Ariel I Jacob; Joseph M Collaco; Sharon A McGrath-Morrow; Lewis H Romer; Chinwe C Unegbu
Journal:  Pulm Circ       Date:  2017-10-03       Impact factor: 3.017

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.